ABSTRACT
Background It is unclear whether diabetes or prediabetes drives adverse treatment outcomes and death in people with tuberculosis (PWTB).
Methods Culture-confirmed PWTB, enrolled in the Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil cohort between 2015 and 2019 (n=756) were stratified based on glycemic status by baseline glycated hemoglobin levels. Unfavorable TB outcome was defined as treatment failure or modification, recurrence or death, whereas favorable outcome was cure or treatment completion. We validated the findings using data from PWTB reported to the Brazilian National System of Diseases Notification (SINAN) during 2015-2019 (n=20,989). Stepwise binary multivariable regression analysis models evaluated associations between glycemic status and unfavorable outcomes.
Results In both cohorts, in univariate analysis, unfavorable outcomes were more frequently associated with drug resistance and HIV infection. Diabetes was associated with unfavorable outcomes in the RePORT (aOR: 2.85, p=0.001) and in SINAN (aOR: 1.56, p=0.040) cohorts. Furthermore, diabetes was associated with higher risk of death in both, RePORT-Brazil (aOR:3.23, p=0.006) and in the SINAN (aOR:2.75, p= 0.047) cohorts.
Conclusion Diabetes was associated with an increased risk of unfavorable outcomes and mortality in Brazilian PWTB. Interventions to improve tuberculosis treatment outcomes in persons with diabetes are needed.
40-word summary of the article’s main point In a multicenter prospective cohort study from Brazil, diabetes was associated with an increased risk of unfavorable treatment outcomes, including mortality, in pulmonary tuberculosis patients. These observations were validated in the Brazilian National Disease Notification System during the same period.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the Intramural Research Program of the Fundacao Oswaldo Cruz, Intramural Research Program of the Fundacao Jose Silveira, Departamento de Ciencia e Tecnologia (DECIT), Secretaria de Ciencia e Tecnologia (SCTIE), Ministerio da Saude (MS), Brazil [25029.000507/2013.07] and the National Institutes of Allergy and Infectious Diseases [U01AI069923]. M.B.A. received a fellowship from the Fundacao de Amparo a Pesquisa da Bahia (FAPESB). M.A.-P. received a fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Finance code: 001). B.B.A., J.R.L.S. and A.K. are senior investigators of the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the principles in the Declaration of Helsinki. The RePORT-Brazil protocol was approved by the institutional review boards at each study site and at Vanderbilt University Medical Center. The protocol, informed consent, and study documents were approved by the institutional review boards at all study sites. The Institional Review Boards and the protocol approval numbers are as follows: (i) Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil (protocol no. 688.067), (ii) Secretaria Municipal de Saude do Rio de Janeiro, Brazil (protocol no. 740.554), (iii) Hospital Universitario Clementino Fraga Filho Rio de Janeiro, Brazil (protocol no. 852.519), (iv) Maternidade Climério de Oliveira, Universidade Federal da Bahia, Salvador, Brazil (protocol no. 723.168), (v) Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil (protocol no. 807.595). Participation was voluntary and written informed consent was obtained from all participants. Participation in RePORT-Brazil was voluntary, and written informed consent was obtained from all participants. All data extracted from SINAN were public and freely accessible. The anonymity of study subjects was preserved; all data were de-identified.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data extracted from SINAN are public and freely accessible (http://www.portalsinan.saude.gov.br/dados-epidemiologicos-sinan). The data from RePORT Brazil can be available upon reasonable request to the corresponding author.
http://www.portalsinan.saude.gov.br/dados-epidemiologicos-sinan
